Clinical Trial Update: Pembrolizumab Maintenance After Enfortumab Vedotin (EV)/Pembro Induction in Front-Line Metastatic Urothelial Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating pembrolizumab maintenance after enfortumab vedotin/pembrolizumab induction as front-line treatment for metastatic urothelial carcinoma …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Unresectable Urothelial Carcinoma
• Urothelial Carcinoma

Drugs mentioned

• Enfortumab Vedotin (enfortumab vedotin)
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Fox Chase Cancer Center | Conditions: Metastatic Urothelial Carcinoma, Unresectable Urothelial Carcinoma | Phase 2 | Status: RECRUITING